Glucose-dependent insulinotropic peptide (GIP) significantly suppressed testosterone production in PCOS mouse models and cell systems, suggesting a new therapeutic angle for hyperandrogenism.
Significant testosterone reductionGIP suppressed androgen biosynthesis in both PCOS mouse models and human adrenal cell cultures
What the researchers found
GIP significantly reduced testosterone secretion in PCOS mouse models and NCI-H295R cells, suppressing androgen biosynthesis through specific molecular pathways identified via RNA sequencing.
Why it matters
PCOS affects up to 13% of women of reproductive age, and hyperandrogenism is its most distressing feature. Current anti-androgen treatments have significant limitations. GIP-based therapies could offer a new approach, especially given the growing availability of GIP-containing drugs like tirzepatide.
The numbers in context
- GIP significantly reduced testosterone in PCOS mice
- Downregulated GIPR, STAR, CYP11A1, and CYP17A1 in ovarian cells
- PSENEN was the most downregulated gene on RNA-seq
- PSENEN knockdown further reduced testosterone production
How the study worked
Combined in vivo (DHEA-induced PCOS mouse model) and in vitro (NCI-H295R adrenal cell line) study using CCK8, flow cytometry, RT-qPCR, Western blot, ELISA, and RNA-seq to assess GIP's effects on androgen synthesis.
Who was studied
DHEA-induced PCOS mouse models and NCI-H295R human adrenal cells. In vivo and in vitro studies of GIP effects on androgen synthesis.
What this study cannot tell us
Animal model — DHEA-induced PCOS may not fully represent human PCOS pathophysiology; NCI-H295R cells are an adrenal cancer cell line, not normal ovarian tissue; dose-response relationships not fully characterized; no human clinical data.
How to read the evidence
Preclinical study combining animal and cell models with comprehensive molecular characterization. Strong mechanistic evidence but no human data yet.
When this study was published
Published in 2025, timely given the rapid expansion of GIP-containing medications like tirzepatide.
The bigger picture
With tirzepatide (a dual GIP/GLP-1 agonist) already on the market, these findings suggest an unexpected benefit for women with PCOS. This could accelerate clinical investigation of tirzepatide and similar drugs for PCOS management.
Questions still open
- Would tirzepatide (a dual GIP/GLP-1 agonist) have anti-androgenic benefits in women with PCOS?
- Does GIP suppress androgens through ovarian or adrenal pathways, or both?
- Could GIP agonism complement existing anti-androgen therapies for PCOS?
Common questions
What is GIP and how is it related to GLP-1 drugs?
Could weight loss drugs help with PCOS?
Read the original research
Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 41(1), 2582506
Citation
Pan, Mengru; Qian, Yifan; Jiang, Linlin; Cao, Chunwei; Li, Lin. (2025). Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 41(1), 2582506. https://doi.org/10.1080/09513590.2025.2582506